Archives

Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025

B AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent productivity platform… Login to continue reading Login…

Read MoreHaier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025

2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

B SHANGHAI, April 30, 2026 /PRNewswire/ — Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest… Login to continue reading Login…

Read More2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

Elite Robots Launches RoboBarista to Revolutionize Self-Service Coffee Experiences in Commercial and Public Spaces

B SHANGHAI, April 30, 2026 /PRNewswire/ — Elite Robots, a global leader in collaborative robotics, today announced RoboBarista, a fully autonomous coffee station designed for high-traffic… Login to continue reading Login…

Read MoreElite Robots Launches RoboBarista to Revolutionize Self-Service Coffee Experiences in Commercial and Public Spaces

Inside the Persefoni Yacht: How Luca Dini’s Vision Transformed a Mariotti Hull Into the Aegean’s Most Beautiful Superyacht

To understand the Persefoni yacht is to understand Luca Dini Design & Architecture — the celebrated Florentine studio that conceived every surface, proportion, and detail… Login to continue reading Login…

Read MoreInside the Persefoni Yacht: How Luca Dini’s Vision Transformed a Mariotti Hull Into the Aegean’s Most Beautiful Superyacht

D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types

B Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes… Login to continue reading Login…

Read MoreD3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types